Dateline City:
WHITEHOUSE STATION, N.J.
Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented
Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data from clinical studies of the companys
investigational, oral, once-daily, fixed-dose combination chronic
hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are
scheduled to be presented at the 65th American Association
for the Study of Liver Diseases (AASLD) Annual Meeting, also known as
The Liver Meeting. The meeting is scheduled to take place at
the John B.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more